Search Results - "Scardino, Epifanio"

Correlation Between Acute and Late Toxicity in 973 Prostate Cancer Patients Treated With Three-Dimensional Conformal External Beam Radiotherapy by Jereczek-Fossa, Barbara A., M.D., Ph.D, Zerini, Dario, M.D, Fodor, Cristiana, M.Sc, Santoro, Luigi, M.Sc, Serafini, Flavia, M.D, Cambria, Raffaella, M.Sc, Vavassori, Andrea, M.D, Cattani, Federica, M.Sc, Garibaldi, Cristina, M.Sc, Gherardi, Federica, M.D, Ferrari, Annamaria, M.D, Rocco, Bernardo, M.D, Scardino, Epifanio, M.D, de Cobelli, Ottavio, M.D, Orecchia, Roberto, M.D

“…Purpose To analyze the correlation between acute and late injury in 973 prostate cancer patients treated with radiotherapy and to evaluate the effect of…”
Get full text

Response to “Urinary Obstruction in Prostate Cancer Patients From the Dutch Trial (68 Gy vs. 78 Gy): Relationships With Local Dose, Acute Effects, and Baseline Characteristics” ( Int J Radiat Oncol Biol Phys 2010 ;78:19–25) by Jereczek-Fossa, Barbara Alicja, M.D., Ph.D, Orecchia, Roberto, M.D, Bonora, Maria, M.D, Scardino, Epifanio, M.D

Get full text

Sensitivity and Detection Rate of a 12-Core Trans-Perineal Prostate Biopsy: Preliminary Report by Rocco, Bernardo, de Cobelli, Ottavio, Leon, Maria Elena, Ferruti, Mario, Mastropasqua, Mauro G., Matei, Deliu Victor, Gazzano, Giacomo, Verweij, Fabrizio, Scardino, Epifanio, Musi, Gennaro, Djavan, Bob, Rocco, Francesco

“…The various prostate biopsy methods are usually compared in terms of the diagnosis rate of prostate cancer. However, the prevalence of cancer in patients with…”
Get full text

Intraoperative Radiotherapy for Locally Advanced Prostate Cancer: Treatment Technique and Ultrasound-based Analysis of Dose Distribution by ORECCHIA, Roberto, JERECZEK-FOSSA, Barbara A, SCARDINO, Epifanio, DE COBELLI, Ottavio, CIOCCA, Mario, VAVASSORI, Andrea, CAMBRIA, Raffaella, CATTANI, Federica, ZERINI, Dario, MATEI, Deliu V, ROCCO, Bernardo, VERWEIJ, Fabrizio

“…Background: To present the technique and dose distribution of intraoperative radiotherapy (IORT) for prostate cancer. Patients and Methods: Pelvic…”
Get full text

Synchronous Collecting Duct Carcinoma and Papillary Renal Cell Carcinoma: A Case Report and Review of the Literature by MATEI, Deliu-Victor, ROCCO, Bernardo, VARELA, Rodolfo, VERWEIJ, Fabrizio, SCARDINO, Epifanio, RENNE, Giuseppe, DE COBELLI, Ottavio

“…The coexistence of multiple and synchronous primary neoplasms in the same organ (including kidney) has only rarely been described in the literature. We herein…”
Get full text

Locally advanced prostate cancer: Biochemical results from a prospective phase II study of intermittent androgen suppression for men with evidence of prostate‐specific antigen recurrence after radiotherapy by Rocco, Bernardo, Scardino, Epifanio, de Cobelli, Ottavio

Get full text

Locally advanced prostate cancer: Biochemical results from a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen recurrence after radiotherapy by Rocco, Bernardo, Scardino, Epifanio, de Cobelli, Ottavio

Get full text

Health-related quality of life in patients with hormone refractory prostate cancer receiving gefitinib by Curigliano, Giuseppe, Spitaleri, Gianluca, De Cobelli, Ottavio, Scardino, Epifanio, Sbanotto, Alberto, de Braud, Filippo

“…Improvements in quality of life (QoL) and disease-related symptoms are key goals in the treatment of hormone refractory prostate cancer (HRPC). Our aim was to…”
Get more information

Gefitinib combined with endocrine manipulation in patients with hormone-refractory prostate cancer: quality of life and surrogate markers of activity by Curigliano, Giuseppe, De Braud, Filippo, Teresa Sandri, Maria, Renne, Giuseppe, Zorzino, Laura, Scardino, Epifanio, Rocco, Bernardo, Spitaleri, Gianluca, De Pas, Tommaso, Noberasco, Cristina, Nolè, Franco, Verweij, Fabrizio, Matei, Victor, De Cobelli, Ottavio

“…We investigated efficacy of gefitinib in hormone-refractory prostate cancer. Between March 2003 and December 2004, 23 patients with hormone-refractory prostate…”
Get full text

Localization of Avidin in Superficial Bladder Cancer: A Potentially New Approach for Radionuclide Therapy by Chinol, Marco, De Cobelli, Ottavio, Trifirò, Giuseppe, Scardino, Epifanio, Bartolomei, Mirco, Verweij, Fabrizio, Papi, Stefano, Matei, Deliu V., Paganelli, Giovanni

“…Objective: To verify whether native avidin, made radioactive through the binding with technetium-99m labeled biotin ( 99 m Tc -biotin), selectively accumulated…”
Get full text

Localization of avidin in superficial bladder cancer: A potentially new approach for radionuclidetherapy by CHINOL, Marco, DE COBELLI, Ottavio, TRIFIRO, Giuseppe, SCARDINO, Epifanio, BARTOLOMEI, Mirco, VERWEIJ, Fabrizio, PAPI, Stefano, MATEI, Deliu V, PAGANELLI, Giovanni

Get full text

Paradoxical stimulation of prolactin secretion by L-dopa in metastatic prostate cancer and its possible role in prostate-cancer-related hyperprolactinemia by Lissoni, P, Mandalà, M, Rovelli, F, Casu, M, Rocco, F, Tancini, G, Scardino, E

“…In addition to sex steroids, prolactin (PRL) may also stimulate prostate cancer growth. Abnormally high blood levels of PRL have been noted in metastatic…”
Get more information

Reversal of clinical resistance to LHRH analogue in metastatic prostate cancer by the pineal hormone melatonin: efficacy of LHRH analogue plus melatonin in patients progressing on LHRH analogue alone by Lissoni, P, Cazzaniga, M, Tancini, G, Scardino, E, Musci, R, Barni, S, Maffezzini, M, Meroni, T, Rocco, F, Conti, A, Maestroni, G

“…Experimental and preliminary clinical studies have suggested that the pineal hormone melatonin (MLT) may stimulate hormone receptor expression on both normal…”
Get more information

A randomized study of low-dose interleukin-2 subcutaneous immunotherapy versus interleukin-2 plus interferon-alpha as first line therapy for metastatic renal cell carcinoma by Lissoni, P, Barni, S, Ardizzoia, A, Andres, M, Scardino, E, Cardellini, P, Della Bitta, R, Tancini, G

“…IL-2 given subcutaneously in combination with interferon-alpha 2b (IFN) appears to induce a response rate comparable to that obtained with IL-2 intravenous…”
Get more information

Lymphocytosis decline is not responsible for tumor progression in cancer patients chronically treated with interleukin-2 by Lissoni, P, Barni, S, Andres, M, Scardino, E, Vigoré, L, Vezzo, R, Rescaldani, R, Tancini, G

“…The antitumor activity of IL-2 is mediated by an increase in lymphocyte number. Moreover, our previous studies have shown that therapy for 1 week/month with…”
Get more information